. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: Eur J Cancer. 2020 May 31;133:112–119. doi: 10.1016/j.ejca.2020.04.007

Table 3.

Cox proportional hazard models of event-free (EFS) and overall survival (EFS) in patients with neuroblastoma.

Heterogeneous vs. Homogeneous MNA (n=1,037)
Variable	Reference Group	EFS		OS
Variable	Reference Group	Hazard Ratio	p-value	Hazard Ratio	p-value
Category of MNA (Heterogeneous vs. Homogeneous)	Homogeneous	0.958	0.8453	0.837	0.4735
Age	<18 months	0.933	0.4961	0.907	0.3720
INSS Stage	Not Stage 4	2.511	<0.0001	2.744	<0.0001
*Heterogeneous MNA vs. Wild-type MYCN* (n=4,972)**
Variable	Reference Group	EFS		OS
Variable	Reference Group	Hazard Ratio	p-value	Hazard Ratio	p-value
MYCN Status (Heterogeneous MNA vs. Wild-type)	Wild-type	1.605	0.0284	1.914	0.0086
Age	<18 months	1.740	<0.0001	3.271	<0.0001
INSS Stage	Not Stage 4	3.583	<0.0001	7.657	<0.0001

Abbreviations: MNA=MYCN amplification